Transcriptional reprogramming during human osteoclast differentiation identifies regulators of osteoclast activity

Abstract

Enhanced osteoclastogenesis and osteoclast activity contribute to the development of osteoporosis, which is characterized by increased bone resorption and inadequate bone formation. As novel antiosteoporotic therapeutics are needed, understanding the genetic regulation of human osteoclastogenesis could help identify potential treatment targets. This study aimed to provide an overview of transcriptional reprogramming during human osteoclast differentiation. Osteoclasts were differentiated from CD14⁺ monocytes from eight female donors. RNA sequencing during differentiation revealed 8 980 differentially expressed genes grouped into eight temporal patterns conserved across donors. These patterns revealed distinct molecular functions associated with postmenopausal osteoporosis susceptibility genes based on RNA from iliac crest biopsies and bone mineral density SNPs. Network analyses revealed mutual dependencies between temporal expression patterns and provided insight into subtype-specific transcriptional networks. The donor-specific expression patterns revealed genes at the monocyte stage, such as filamin B (FLNB) and oxidized low-density lipoprotein receptor 1 (OLR1, encoding LOX-1), that are predictive of the resorptive activity of mature osteoclasts. The expression of differentially expressed G-protein coupled receptors was strong during osteoclast differentiation, and these receptors are associated with bone mineral density SNPs, suggesting that they play a pivotal role in osteoclast differentiation and activity. The regulatory effects of three differentially expressed G-protein coupled receptors were exemplified by in vitro pharmacological modulation of complement 5 A receptor 1 (C5AR1), somatostatin receptor 2 (SSTR2), and free fatty acid receptor 4 (FFAR4/GPR120). Activating C5AR1 enhanced osteoclast formation, while activating SSTR2 decreased the resorptive activity of mature osteoclasts, and activating FFAR4 decreased both the number and resorptive activity of mature osteoclasts. In conclusion, we report the occurrence of transcriptional reprogramming during human osteoclast differentiation and identified SSTR2 and FFAR4 as antiresorptive G-protein coupled receptors and FLNB and LOX-1 as potential molecular markers of osteoclast activity. These data can help future investigations identify molecular regulators of osteoclast differentiation and activity and provide the basis for novel antiosteoporotic targets.

References

1. Bolamperti, S., Villa, I.& Rubinacci, A. Bone remodeling: an operational process ensuring survival and bone mechanical competence. Bone Res. 10, 48(2022).
2. Arai, F.et al.Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J. Exp. Med. 190, 1741-1754 (1999).
3. Li, X.et al.p38 MAPK-mediated signals are required for inducing osteoclast differentiation but not for osteoclast function. Endocrinology 143, 3105-3113 (2002).
4. Moon, J. B.et al.Akt induces osteoclast differentiation through regulating the GSK3β/NFATc1 signaling cascade. J. Immunol. 188, 163-169 (2012).
5. Takayanagi, H.et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell 3, 889-901 (2002).
6. Boyle, W. J., Simonet, W. S. & Lacey, D. L. Osteoclast differentiation and activation. Nature 423, 337-342 (2003).
7. Simonet, W. S.et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89, 309-319 (1997).
8. D'Amelio, P. et al. Spontaneous osteoclast formation from peripheral blood mononuclear cells in postmenopausal osteoporosis. FASEB J. 19, 410-412 (2005).
9. Streicher, C.et al.Estrogen regulates bone turnover by targeting RANKL expression in bone lining cells. Sci. Rep. 7, 6460(2017).
10. D'Amelio, P.et al. Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: a key mechanism in osteoporosis. Bone 43, 92-100 (2008).
11. Eastell, R.et al.Postmenopausal osteoporosis. Nat. Rev. Dis. Primers. 2, 16069(2016).
12. Rizzoli, R.et al.Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif. Tissue Int. 89, 91-104 (2011).
13. Cipriani C., Pepe J.,Minisola S.& Lewiecki, E. M. Adverse effects of media reports on the treatment of osteoporosis. J. Endocrinol. Invest. 41, 1359-1364 (2018).
14. Pazianas, M. & Abrahamsen, B. Safety of bisphosphonates. Bone 49, 103-110 (2011).
15. Fink, H. A.et al.Long-term drug therapy and drug discontinuations and holidays for osteoporosis fracture prevention: a systematic review. Ann. Intern. Med. 171, 37-50 (2019).
16. Møller A. M.J. et al. Fusion potential of human osteoclasts in vitro reflects age, menopause, and in vivo bone resorption levels of their donors-A possible involvement of DC-STAMP. Int. J. Mol. Sci. 21, 6368(2020).
17. Hansen, M. S.et al.GIP reduces osteoclast activity and improves osteoblast survival in primary human bone cells. Eur. J. Endocrinol. 188, lvac004 (2023).
18. Gallois, A.et al.Genome-wide expression analyses establish dendritic cells as a new osteoclast precursor able to generate bone-resorbing cells more efficiently than monocytes. J. Bone Miner. Res. 25, 661-672 (2010).
19. Lee B., Kim J. H., Jung J. H., Kim T. H.& Ji, J. D. TREM-1, a negative regulator of human osteoclastogenesis. Immunol. Lett. 171, 50-59 (2016).
20. Rashid, S.et al.Identification of differentially expressed genes and molecular pathways involved in osteoclastogenesis using RNA-seq. Genes (Basel) 14, 916(2023).
21. Riihonen, R.et al. Membrane-bound carbonic anhydrases in osteoclasts. Bone 40, 1021-1031 (2007).
22. Lehenkari P., Hentunen T. A., Laitala-Leinonen, T., Tuukkanen, J. & Vaananen, H. K. Carbonic anhydrase II plays a major role in osteoclast differentiation and bone resorption by effecting the steady state intracellular pH and Ca2+. Exp. Cell Res. 242, 128-137 (1998).
23. Dai, R.et al.Cathepsin K: the action in and beyond bone. Front. Cell Dev. Biol. 8, 433(2020).
24. Hayman, A. R. Tartrate-resistant acid phosphatase (TRAP) andthe osteoclast/ immune cell dichotomy. Autoimmunity 41, 218-223 (2008).
25. Kikuta J.& Ishii, M. Osteoclast migration, differentiation and function: novel therapeutic targets for rheumatic diseases. Rheumatology (Oxford) 52, 226-234 (2013).
26. Destaing, O.et al. The tyrosine kinase activity of c-Src regulates actin dynamics and organization of podosomes in osteoclasts. Mol. Biol. Cell 19, 394-404 (2008).
27. Arnett T. R.Extracellular pH regulates bone cell function. J. Nutr. 138, 415S-418S (2008).
28. Muñoz-Fuentes,V. et al. The International Mouse Phenotyping Consortium (IMPC): a functional catalogue of the mammalian genome that informs conservation. Conserv. Genet. 19, 995-1005 (2018).
29. Jemtland, R.et al.Molecular disease map of bone characterizing the postmenopausal osteoporosis phenotype. J. Bone Miner. Res. 26, 1793-1801 (2011).
30. Rumpler, M.et al.Osteoclasts on bone and dentin in vitro: mechanism of trail formation and comparison of resorption behavior. Calcif. Tissue Int. 93, 526-539 (2013).
31. Zhou, Y.et al.A novel approach for correction of crosstalk effects in pathway analysis and its application in osteoporosis research. Sci. Rep. 8, 668(2018).
32. Liu, Y. Z.et al.Attenuated monocyte apoptosis, a new mechanism for osteoporosis suggested by a transcriptome-wide expression study of monocytes. PLoS One 10, e0116792 (2015).
33. Morris, J. A.et al.An atlas of genetic influences on osteoporosis in humans and mice. Nat. Genet. 51, 258-266 (2019).
34. Coates, B. A.et al. Transcriptional profiling of intramembranous and endochondral ossification after fracture in mice. Bone 127, 577-591 (2019).
35. Balwierz, P. J.et al.ISMARA: automated modeling of genomic signals as a democracy of regulatory motifs. Genome Res. 24, 869-884 (2014).
36. Ikeda, F.et al.Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. J. Clin. Invest. 114, 475-484 (2004).
37. Omata, Y.et al.Interspecies single-cell RNA-seq analysis reveals the novel trajectory of osteoclast differentiation and therapeutic targets. JBMR Plus 6, e10631 (2022).
38. Musa J., Aynaud M. M., Mirabeau O., Delattre O.& Grunewald, T. G. MYBL2 (BMyb): a central regulator of cell proliferation, cell survival and differentiation involved in tumorigenesis. Cell Death Dis. 8, e2895(2017).
39. Signorelli, M., Vinciotti, V.& Wit, E. C. NEAT: an efficient network enrichment analysis test. BMC Bioinformatics 17, 352 (2016).
40. McDonald, M. M.et al. Osteoclasts recycle via osteomorphs during RANKLstimulated bone resorption. Cell 184, 1330-1347.e1313 (2021).
41. Hauser A. S., Attwood M. M., Rask-Andersen, M., Schioth, H. B. & Gloriam, D. E. Trends in GPCR drug discovery: new agents, targets and indications. Nat. Rev. Drug Discov. 16, 829-842 (2017).
42. Diepenhorst, N.et al.G protein-coupled receptors as anabolic drug targets in osteoporosis. Pharmacol. Ther. 184, 1-12 (2018).
43. Luo J., Sun P., Siwko S., Liu M.& Xiao, J. The role of GPCRs in bone diseases and dysfunctions. Bone Res. 7, 19(2019).
44. Chambers T. J.& Moore, A. The sensitivity of isolated osteoclasts to morphological transformation by calcitonin. J. Clin. Endocrinol. Metab. 57, 819-824 (1983).
45. Kooistra, A. J.et al.GPCRdb in 2021: integrating GPCR sequence, structure and function. Nucleic Acids Res. 49, D335-D343 (2021).
46. Luo, J.et al.LGR4 is a receptor for RANKL and negatively regulates osteoclast differentiation and bone resorption. Nat. Med. 22, 539-546 (2016).
47. Hauser, A. S.et al.Common coupling map advances GPCR-G protein selectivity. Elife 11, e74107 (2022).
48. Pandey, S.et al.Partial ligand-receptor engagement yields functional bias at the human complement receptor, C5aR1. J. Biol. Chem. 294, 9416-9429 (2019).
49. Kovtun, A.et al.Complement receptors C5aR1 and C5aR2 act differentially during the early immune response after bone fracture but are similarly involved in bone repair. Sci. Rep. 7, 14061(2017).
50. Modinger Y., Loffler B., Huber-Lang, M. & Ignatius, A. Complement involvement in bone homeostasis and bone disorders. Semin. Immunol. 37, 53-65 (2018).
51. Pobanz J. M., Reinhardt R. A., Koka S.& Sanderson, S. D. C5a modulation of interleukin-1 beta-induced interleukin-6 production by human osteoblast-like cells. J. Periodontal Res. 35, 137-145 (2000).
52. Gorman, D. M.et al.Development of potent and selective agonists for complement C5a receptor 1 with in vivo activity. J. Med. Chem. 64, 16598-16608 (2021).
53. Woodruff, T. M.et al.Increased potency of a novel complement factor 5a receptor antagonist in a rat model of inflammatory bowel disease. J. Pharmacol. Exp. Ther. 314, 811-817 (2005).
54. Hudson, B. D.et al.The pharmacology of TUG-891, a potent and selective agonist of the free fatty acid receptor 4 (FFA4/GPR120), demonstrates both potential opportunity and possible challenges to therapeutic agonism. Mol. Pharmacol. 84, 710-725 (2013).
55. Kim, H. J.et al.G protein-coupled receptor 120 signaling negatively regulates osteoclast differentiation, survival, and function. J. Cell Physiol. 231, 844-851 (2016).
56. Kasonga A. E., Deepak V., Kruger M. C.& Coetzee, M. Arachidonic acid and docosahexaenoic acid suppress osteoclast formation and activity in human CD14+ monocytes, in vitro. PLoS One 10, e0125145 (2015).
57. Shimpukade B., Hudson B. D., Hovgaard C. K., Milligan G.& Ulven, T. Discovery of a potent and selective GPR120 agonist. J. Med. Chem. 55, 4511-4515 (2012).
58. Rocheville, M.et al.Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. J. Biol. Chem. 275, 7862-7869 (2000).
59. Bo, Q.et al.Structural insights into the activation of somatostatin receptor 2 by cyclic SST analogues. Cell Discov. 8, 47(2022).
60. Clowes J. A., Allen H. C., Prentis D. M., Eastell R.& Blumsohn, A. Octreotide abolishes the acute decrease in bone turnover in response to oral glucose. J. Clin. Endocrinol. Metab. 88, 4867-4873 (2003).
61. Ren, S. G.et al.Functional association of somatostatin receptor subtypes 2 and 5 in inhibiting human growth hormone secretion. J. Clin. Endocrinol. Metab. 88, 4239-4245 (2003).
62. Love, M. I., Huber, W.& Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550(2014).
63. Cody, J. J.et al.A simplified method for the generation of human osteoclasts in vitro. Int. J. Biochem. Mol. Biol. 2, 183-189 (2011).
64. Sorensen, M. G.et al.Characterization of osteoclasts derived from CD14+ monocytes isolated from peripheral blood. J. Bone Miner. Metab. 25, 36-45 (2007).
65. Hassan, M. Q.et al.HOXA10 controls osteoblastogenesis by directly activating bone regulatory and phenotypic genes. Mol. Cell Biol. 27, 3337-3352 (2007).
66. Gordon, J. A.et al.Pbx1 represses osteoblastogenesis by blocking Hoxa10-mediated recruitment of chromatin remodeling factors. Mol. Cell Biol. 30, 3531-3541 (2010).
67. Wang, Y.et al.Obesity regulates miR-467/HoxA10 axis on osteogenic differentiation and fracture healing by BMSC-derived exosome LncRNA H19. J. Cell Mol. Med. 25, 1712-1724 (2021).
68. Blixt, N.et al.Loss of myocyte enhancer factor 2 expression in osteoclasts leads to opposing skeletal phenotypes. Bone 138, 115466 (2020).
69. Leupin, O.et al.Control of the SOST bone enhancer by PTH using MEF2 transcription factors. J. Bone Miner. Res. 22, 1957-1967 (2007).
70. D'Angelo, R.et al. Inhibition of osteoclast activity by complement regulation with DF3016A, a novel small-molecular-weight C5aR inhibitor. Biomed. Pharmacother. 123, 109764(2020).
71. Toyama, C.et al.Effect of a C5a receptor antagonist on macrophage function in an intestinal transplant rat model. Transpl. Immunol. 72, 101559(2022).
72. Levaot, N.et al. Osteoclast fusion is initiated by a small subset of RANKLstimulated monocyte progenitors, which can fuse to RANKL-unstimulated progenitors. Bone 79, 21-28 (2015).
73. Hofland L. J.& Lamberts, S. W. Somatostatin receptors and disease: role of receptor subtypes. Baillieres Clin. Endocrinol. Metab. 10, 163-176 (1996).
74. Tulipano, G.et al. Characterization of new selective somatostatin receptor subtype-2 (sst2) antagonists, BIM-23627 and BIM-23454. Effects of BIM-23627 on GH release in anesthetized male rats after short-term high-dose dexamethasone treatment. Endocrinology 143, 1218-1224 (2002).
75. Milligan G., Shimpukade B., Ulven T.& Hudson, B. D. Complex pharmacology of free fatty acid receptors. Chem. Rev. 117, 67-110 (2017).
76. Gendaszewska-Darmach, E., Drzazga, A. & Koziolkiewicz, M. Targeting GPCRs activated by fatty acid-derived lipids in type 2 diabetes. Trends Mol. Med. 25, 915-929 (2019).
77. Carullo, G.et al.GPR120/FFAR4 pharmacology: focus on agonists in type 2 diabetes mellitus drug discovery. J. Med. Chem. 64, 4312-4332 (2021).
78. Sorensen, K. V.et al.Effects of delayed-release olive oil and hydrolyzed pine nut oil on glucose tolerance, incretin secretion and appetite in humans. Nutrients 13, 3407 (2021).
79. Kishikawa, A.et al.Docosahexaenoic acid inhibits inflammation-induced osteoclast formation and bone resorption in vivo through GPR120 by inhibiting TNF-alpha production in macrophages and directly inhibiting osteoclast formation. Front. Endocrinol (Lausanne) 10, 157(2019).
80. Ahn, S. H.et al. Free fatty acid receptor 4 (GPR120) stimulates bone formation and suppresses bone resorption in the presence of elevated n-3 fatty acid levels. Endocrinology 157, 2621-2635 (2016).
81. Wilson, S. G.et al.Common sequence variation in FLNB regulates bone structure in women in the general population and FLNB mRNA expression in osteoblasts in vitro. J. Bone Miner. Res. 24, 1989-1997 (2009).
82. Krakow, D.et al.Mutations in the gene encoding filamin B disrupt vertebral segmentation, joint formation and skeletogenesis. Nat. Genet. 36, 405-410 (2004).
83. Zhou, X.et al. Filamin B deficiency in mice results in skeletal malformations and impaired microvascular development. Proc. Natl. Acad. Sci. USA 104, 3919-3924 (2007).
84. Farrington-Rock, C. et al. Disruption of the Flnb gene in mice phenocopies the human disease spondylocarpotarsal synostosis syndrome. Hum. Mol. Genet. 17, 631-641 (2008).
85. Nakayachi, M.et al. Lectin-like oxidized low-density lipoprotein receptor-1 abrogation causes resistance to inflammatory bone destruction in mice, despite promoting osteoclastogenesis in the steady state. Bone 75, 170-182 (2015).
86. Schoenmaker, T.et al.Transcriptomic differences underlying the activin-a induced large osteoclast formation in both healthy control and fibrodysplasia ossificans progressiva osteoclasts. Int. J. Mol. Sci. 24, 6822(2023).
87. March, D. R.et al.Potent cyclic antagonists of the complement C5a receptor on human polymorphonuclear leukocytes. Relationships between structures and activity. Mol. Pharmacol. 65, 868-879 (2004).
88. Shimon, I.et al.Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. J. Clin. Invest. 99, 789-798 (1997).
89. Merrild, D. M.et al.Pit- and trench-forming osteoclasts: a distinction that matters. Bone Res. 3, 15032(2015).
90. Dobin, A.et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15-21 (2012).
91. Heinz, S.et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol. Cell 38, 576-589 (2010).
92. Gillespie, M.et al.The reactome pathway knowledgebase 2022. Nucleic Acids Res. 50, D687-d692 (2022).
93. Young M. D., Wakefield M. J., Smyth G. K.& Oshlack, A. Gene ontology analysis for RNA-seq: accounting for selection bias. Genome Biol. 11, R14(2010).
94. Ritchie, M. E.et al.limma powers differential expression analyses for RNAsequencing and microarray studies. Nucleic Acids Res. 43, e47(2015).
95. Korotkevich, G., Sukhov, V. & Sergushichev, A. Fast gene set enrichment analysis. bioRxiv, 060012, https://doi.org/10.1101/060012 (2019).
96. Kavaliauskaite G.& Madsen, J. G. S. Automatic quality control of single-cell and single-nucleus RNA-seq using valiDrops. NAR Genom. Bioinform. 5, lqad101 (2023).
97. Hao, Y.et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573-3587.e3529 (2021).
98. Soe K.& Delaisse, J. M. Glucocorticoids maintain human osteoclasts in the active mode of their resorption cycle. J. Bone Miner. Res. 25, 2184-2192 (2010).
99. Hobolt-Pedersen, A. S., Delaissé, J. M. & Søe, K. Osteoclast fusion is based on heterogeneity between fusion partners. Calcif. Tissue Int. 95, 73-82 (2014).
100. Moura, S. R.et al.Stage-specific modulation of multinucleation, fusion and resorption by the long non-coding RNA DLEU1 and miR-16 in human primary osteoclasts. bioRxiv, 2023.2010.2024.563436, https://doi.org/10.1101/2023.10.24.563436 (2023).

Funding

Morten Frost ([e-mail]) or Alexander Rauch ([e-mail])